Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4051-4060 Newer>

BusinessWeek September 3, 2007 Brian Burnsed	Texas Instruments: Processing Away The Pain Health-care innovations are coming from an unexpected source: Texas Instruments.
Chemistry World August 23, 2007 Richard Van Noorden	How Good Cholesterol Turns Bad Chemists have peered into the depths of HDL, which protects against heart disease, to explain why it can become harmful. The research may also suggest an explanation for the near-billion-dollar failure of Pfizer's blockbuster heart drug, torcetrapib, in recent clinical trials.
The Motley Fool August 23, 2007 Brian Orelli	Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting.
The Motley Fool August 22, 2007 Brian Orelli	Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low.
The Motley Fool August 22, 2007 Brian Orelli	Regulating the Drug Pushers The FDA might get a little tougher on drug ads, following a report that they may not be watching advertisers claims closely enough, or warning patients about side effects strongly enough.
The Motley Fool August 22, 2007 Ryan Fuhrmann	Upbeat About Medtronic The future looks bright at medical-device firm Medtronic, and the stock price is reasonable. First quarter sales grew, as overseas revenue improved an impressive 16%.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
The Motley Fool August 21, 2007 Brian Orelli	Pushing Pills Spending on drug lobbying increases. What do companies have to show for it? The key for investors is to find drug companies that are spending their money wisely.
The Motley Fool August 21, 2007 Brian Lawler	Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year.
<Older 4051-4060 Newer> Return to current articles.